Rain Enhancement Technologies Holdco, Inc. (RAIN) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and welcome to the RAIN Therapeutics Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I'd like to turn the conference over to Bob Yeti. Please go ahead. Thank you, Operator, and good afternoon, everyone. With me today on the call are Avinash Balanki, Chief Executive Officer of RAIN Therapeutics, Nelson Kabat-Juan, SVP of Finance. During today's call, Avanesh will provide an overall business update, including RAINN's clinical programs and research efforts, and Nelson will review the financials. Before we begin, I'd like to remind you that statements made during this conference call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon RAINN's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results may differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, as described in RAINN's annual report on Form 10-K for the year ended December 31, 2021, and subsequent filings with the Securities and Exchange Commission. All forward-looking statements made during this conference call are based on management's assumptions and estimates as of today, August 4th, 2022. RAINN undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after today, except as required by law. With that said, it's my pleasure to turn the call over to Avinash Belanki. CEO of Varian Therapeutics. Abhinish. Thank you, Bob. And thanks to everyone for joining us for our second quarter earnings call. We are pleased to share updates today on our two ...